Vertex taps Verve for gene editing pact — buying a chunk of shares — as Sek Kathiresan steers base editing into clinic - Endpoints News

Although Verve Therapeutics did not come up with a gene editing technology itself, its work applying base editing in cardiovascular diseases — going from launch to first-in-human dosing in just over three years — has caught the eye of Vertex. Vertex is handin…

In June, many brands change their logo colors to rainbow hues to show support for the LGBTQ+ community during Pride Month — and that includes pharma companies. This year the list of pharmas using mul… [+563 chars]

full article...